DBV, BioNet-Asia study needle-free pertussis booster vaccination

DBV Technologies (NSDQ:DBVT) and BioNet-Asia said today that the independent Data & Safety Monitoring Board positively reviewed DBV’s needle-free vaccine patch technology, Viaskin, and that enrollment in a Phase I trial for booster immunization against pertussis will continue into the 2nd dosing cohort. The Viaskin pertussis booster vaccination program will test the ability of DBV’s needle-free vaccine tech to epicutaneously deliver 2 different doses of BioNet’s genetically detoxified pertussis toxin, in the hopes of boosting immunity against whooping cough. The study enrolled 60 adults, ranging from 18 to 40 years old, who were vaccinated against pertussis as a child. The Viaskin patches will be applied for 48 hours, with a 2 week interval between applications. Get the full story at our sister site, Drug Delivery Business News The post DBV, BioNet-Asia study needle-free pertussis booster vaccination appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory BioNet-Asia DBV Technologies Source Type: news